Interpretation and use of FRAX in clinical practice von Kanis, J. A., Hans, D., Cooper, C., Baim, S., Bilezikian, J. P., Binkley, N., Cauley, J. A., Compston, J. E., Dawson-Hughes, B., El-Hajj Fuleihan, G., Johansson, H., Leslie, W. D., Lewiecki, E. M., Luckey, M., Oden, A., Papapoulos, S. E., Poiana, C., Rizzoli, R., Wahl, D. A., McCloskey, E. V.

Volltext

SP0169 Pharmacological Management of Osteoporosis von Papapoulos, S.

Volltext

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study von McCloskey, E., Rathi, J., Heijmans, S., Blagden, M., Cortet, B., Czerwinski, E., Hadji, P., Payer, J., Palmer, K., Stad, R., O’Kelly, J., Papapoulos, S.

Volltext

SP0011 Modern Treatment of Osteoporosis; The First 5 Years von Papapoulos, S.

Volltext

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial von Bone, H. G., Dempster, D. W., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., Verbruggen, N., Leung, A. T., Lombardi, A.

Volltext

Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site von Malgo, F., Hamdy, N.A.T., Papapoulos, S.E., Appelman-Dijkstra, N.M.

Volltext

Sclerostin: Current Knowledge and Future Perspectives von Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., van Bezooijen, R. L.

Volltext

Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures von Schoeb, M., Winter, E. M., Malgo, F., Schipper, I. B., van der Wal, R. J. P., Papapoulos, S. E., Appelman-Dijkstra, N. M.

Volltext

Denosumab for the treatment of primary pediatric osteoporosis von Anastasilakis, A.D., Makras, P., Doulgeraki, A., Polyzos, S.A., Guarnieri, V., Papapoulos, S.E.

Volltext

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study von Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.

Volltext

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls von van Lierop, A H, Witteveen, J E, Hamdy, N A T, Papapoulos, S E

Volltext

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies von Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J-Y., Muñoz Torres, M., Wang, A., Bone, H. G.

Volltext

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension von Papapoulos, Socrates, Chapurlat, Roland, Libanati, Cesar, Brandi, Maria Luisa, Brown, Jacques P, Czerwiński, Edward, Krieg, Marc-Antoine, Man, Zulema, Mellström, Dan, Radominski, Sebastião C, Reginster, Jean-Yves, Resch, Heinrich, Ivorra, José A Román, Roux, Christian, Vittinghoff, Eric, Austin, Matthew, Daizadeh, Nadia, Bradley, Michelle N, Grauer, Andreas, Cummings, Steven R, Bone, Henry G

Volltext

Goal-directed treatment of osteoporosis in Europe von Kanis, J. A., McCloskey, E., Branco, J., Brandi, M.-L., Dennison, E., Devogelaer, J.-P., Ferrari, S., Kaufman, J.-M., Papapoulos, S., Reginster, J.-Y., Rizzoli, R.

Volltext

Bisphosphonates von Papapoulos, S

Volltext

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International... von Rizzoli, R, Åkesson, K, Bouxsein, M, Kanis, J. A, Napoli, N, Papapoulos, S, Reginster, J.-Y, Cooper, C

Volltext

Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper von Goldhahn, J., Féron, J.-M., Kanis, J., Papapoulos, S., Reginster, J.-Y., Rizzoli, R., Dere, W., Mitlak, B., Tsouderos, Y., Boonen, S.

Volltext

Sclerostin in Mineralized Matrices and van Buchem Disease von van Bezooijen, R.L., Bronckers, A.L., Gortzak, R.A., Hogendoorn, P.C.W., van der Wee-Pals, L., Balemans, W., Oostenbroek, H.J., Van Hul, W., Hamersma, H., Dikkers, F.G., Hamdy, N.A.T., Papapoulos, S.E., Löwik, C.W.G.M.

Volltext

Bone fragility in patients affected by congenital diseases non skeletal in origin von Masi, L., Ferrari, S., Javaid, M. K., Papapoulos, S., Pierroz, D. D., Brandi, M. L.

Volltext

Serum Dickkopf 1 Levels in Sclerostin Deficiency von van Lierop, A. H, Moester, M. J. C, Hamdy, N. A. T, Papapoulos, S. E

Volltext